The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| EYEN | -86.94% | -97.97% | -54.15% | -99% |
| S&P | +19.61% | +98.99% | +14.75% | +141% |
Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The firm is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression, and mydriasis. The company was founded by Sean Ianchulev on March 12, 2014 and is headquartered in New York, NY.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | -100.0% |
| Gross Profit | -$0.08M | 90.1% |
| Gross Margin | -413.85% | 6224.6% |
| Market Cap | $29.92M | 6.3% |
| Market Cap / Employee | $2.14M | 0.0% |
| Employees | 14 | -75.4% |
| Net Income | -$8.69M | 21.4% |
| EBITDA | -$8.28M | 3.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $7.53M | 227.4% |
| Inventory | 0 | -100.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $7.99M | 44.8% |
| Short Term Debt | $0.48M | -95.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -107.21% | 47.0% |
| Return On Invested Capital | -6.67% | 116.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$3.47M | 57.8% |
| Operating Free Cash Flow | -$3.45M | 57.8% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 12.00 | -1.34 | 0.32 | -3.02 | -119.53% |
| Price to Sales | 1128.86 | 232.23 | 35.90 | 821.96 | -18.21% |
| Price to Tangible Book Value | -1485.14 | -419.73 | -0.49 | -3.02 | -99.42% |
| Enterprise Value to EBITDA | -5.93 | -2.80 | -3.26 | -4.53 | -14.12% |
| Return on Equity | -368.0% | -914.7% | -388.0% | -228.7% | 10.06% |
| Total Debt | $13.04M | $11.25M | $11.17M | $8.47M | -46.05% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
